256 related articles for article (PubMed ID: 23678878)
1. Current pathways for epidemiological research in amyotrophic lateral sclerosis.
Factor-Litvak P; Al-Chalabi A; Ascherio A; Bradley W; Chío A; Garruto R; Hardiman O; Kamel F; Kasarskis E; McKee A; Nakano I; Nelson LM; Eisen A
Amyotroph Lateral Scler Frontotemporal Degener; 2013 May; 14 Suppl 1(Suppl 1):33-43. PubMed ID: 23678878
[TBL] [Abstract][Full Text] [Related]
2. Prevalence of amyotrophic lateral sclerosis - United States, 2010-2011.
Mehta P; Antao V; Kaye W; Sanchez M; Williamson D; Bryan L; Muravov O; Horton K; ;
MMWR Suppl; 2014 Jul; 63(7):1-14. PubMed ID: 25054277
[TBL] [Abstract][Full Text] [Related]
3. Is exposure to cyanobacteria an environmental risk factor for amyotrophic lateral sclerosis and other neurodegenerative diseases?
Bradley WG; Borenstein AR; Nelson LM; Codd GA; Rosen BH; Stommel EW; Cox PA
Amyotroph Lateral Scler Frontotemporal Degener; 2013 Sep; 14(5-6):325-33. PubMed ID: 23286757
[TBL] [Abstract][Full Text] [Related]
4. The cyanobacteria derived toxin Beta-N-methylamino-L-alanine and amyotrophic lateral sclerosis.
Banack SA; Caller TA; Stommel EW
Toxins (Basel); 2010 Dec; 2(12):2837-50. PubMed ID: 22069578
[TBL] [Abstract][Full Text] [Related]
5. Spatial clustering of amyotrophic lateral sclerosis and the potential role of BMAA.
Caller TA; Field NC; Chipman JW; Shi X; Harris BT; Stommel EW
Amyotroph Lateral Scler; 2012 Jan; 13(1):25-32. PubMed ID: 22214351
[TBL] [Abstract][Full Text] [Related]
6. Prevalence of Amyotrophic Lateral Sclerosis - United States, 2012-2013.
Mehta P; Kaye W; Bryan L; Larson T; Copeland T; Wu J; Muravov O; Horton K
MMWR Surveill Summ; 2016 Aug; 65(8):1-12. PubMed ID: 27490513
[TBL] [Abstract][Full Text] [Related]
7. Searching for a link between the L-BMAA neurotoxin and amyotrophic lateral sclerosis: a study protocol of the French BMAALS programme.
Delzor A; Couratier P; Boumédiène F; Nicol M; Druet-Cabanac M; Paraf F; Méjean A; Ploux O; Leleu JP; Brient L; Lengronne M; Pichon V; Combès A; El Abdellaoui S; Bonneterre V; Lagrange E; Besson G; Bicout DJ; Boutonnat J; Camu W; Pageot N; Juntas-Morales R; Rigau V; Masseret E; Abadie E; Preux PM; Marin B
BMJ Open; 2014 Sep; 4(8):e005528. PubMed ID: 25180055
[TBL] [Abstract][Full Text] [Related]
8. Studies of Environmental Risk Factors in Amyotrophic Lateral Sclerosis (ALS) and a Phase I Clinical Trial of L-Serine.
Bradley WG; Miller RX; Levine TD; Stommel EW; Cox PA
Neurotox Res; 2018 Jan; 33(1):192-198. PubMed ID: 28527102
[TBL] [Abstract][Full Text] [Related]
9. A cluster of amyotrophic lateral sclerosis in New Hampshire: a possible role for toxic cyanobacteria blooms.
Caller TA; Doolin JW; Haney JF; Murby AJ; West KG; Farrar HE; Ball A; Harris BT; Stommel EW
Amyotroph Lateral Scler; 2009; 10 Suppl 2():101-8. PubMed ID: 19929741
[TBL] [Abstract][Full Text] [Related]
10. The epidemiology of amyotrophic lateral sclerosis.
Talbott EO; Malek AM; Lacomis D
Handb Clin Neurol; 2016; 138():225-38. PubMed ID: 27637961
[TBL] [Abstract][Full Text] [Related]
11. Identification of risk factors associated with onset and progression of amyotrophic lateral sclerosis using systematic review and meta-analysis.
Wang MD; Little J; Gomes J; Cashman NR; Krewski D
Neurotoxicology; 2017 Jul; 61():101-130. PubMed ID: 27377857
[TBL] [Abstract][Full Text] [Related]
12. Beyond Guam: the cyanobacteria/BMAA hypothesis of the cause of ALS and other neurodegenerative diseases.
Bradley WG; Mash DC
Amyotroph Lateral Scler; 2009; 10 Suppl 2():7-20. PubMed ID: 19929726
[TBL] [Abstract][Full Text] [Related]
13. Environmental risk factors for amyotrophic lateral sclerosis: methodological issues in epidemiologic studies.
Vinceti M; Fiore M; Signorelli C; Odone A; Tesauro M; Consonni M; Arcolin E; Malagoli C; Mandrioli J; Marmiroli S; Sciacca S; Ferrante M
Ann Ig; 2012; 24(5):407-15. PubMed ID: 23193897
[TBL] [Abstract][Full Text] [Related]
14. β-N-methylamino-l-alanine causes neurological and pathological phenotypes mimicking Amyotrophic Lateral Sclerosis (ALS): the first step towards an experimental model for sporadic ALS.
de Munck E; Muñoz-Sáez E; Miguel BG; Solas MT; Ojeda I; Martínez A; Gil C; Arahuetes RM
Environ Toxicol Pharmacol; 2013 Sep; 36(2):243-255. PubMed ID: 23688553
[TBL] [Abstract][Full Text] [Related]
15. Sporadic amyotrophic lateral sclerosis as an infectious disease: a possible role of cyanobacteria?
Stipa G; Taiuti R; de Scisciolo G; Arnetoli G; Tredici MR; Biondi N; Barsanti L; Lolli F
Med Hypotheses; 2006; 67(6):1363-71. PubMed ID: 16890380
[TBL] [Abstract][Full Text] [Related]
16. Preliminary Results of National Amyotrophic Lateral Sclerosis (ALS) Registry Risk Factor Survey Data.
Bryan L; Kaye W; Antao V; Mehta P; Muravov O; Horton DK
PLoS One; 2016; 11(4):e0153683. PubMed ID: 27124833
[TBL] [Abstract][Full Text] [Related]
17. Aggregation of neurologic and neuropsychiatric disease in amyotrophic lateral sclerosis kindreds: a population-based case-control cohort study of familial and sporadic amyotrophic lateral sclerosis.
Byrne S; Heverin M; Elamin M; Bede P; Lynch C; Kenna K; MacLaughlin R; Walsh C; Al Chalabi A; Hardiman O
Ann Neurol; 2013 Nov; 74(5):699-708. PubMed ID: 23836460
[TBL] [Abstract][Full Text] [Related]
18. CDC Grand Rounds: National Amyotrophic Lateral Sclerosis (ALS) Registry Impact, Challenges, and Future Directions.
Mehta P; Horton DK; Kasarskis EJ; Tessaro E; Eisenberg MS; Laird S; Iskander J
MMWR Morb Mortal Wkly Rep; 2017 Dec; 66(50):1379-1382. PubMed ID: 29267263
[TBL] [Abstract][Full Text] [Related]
19. Linking β-methylamino-L-alanine exposure to sporadic amyotrophic lateral sclerosis in Annapolis, MD.
Field NC; Metcalf JS; Caller TA; Banack SA; Cox PA; Stommel EW
Toxicon; 2013 Aug; 70():179-83. PubMed ID: 23660330
[TBL] [Abstract][Full Text] [Related]
20. Mapping amyotrophic lateral sclerosis lake risk factors across northern New England.
Torbick N; Hession S; Stommel E; Caller T
Int J Health Geogr; 2014 Jan; 13():1. PubMed ID: 24383521
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
